Vir Biotechnology, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • July 6th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
Vir Biotechnology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ● ] shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”, and such shares the “Firm Shares”) and, at the election of the Underwriters, up to [ ● ] additional shares (the “Optional Shares”) of Common Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
DEVELOPMENT AND MANUFACTURING COLLABORATION AGREEMENT by and between VIR BIOTECHNOLOGY, INC. and WUXI BIOLOGICS (HONG KONG) LIMITED 25 February 2020Development and Manufacturing Collaboration Agreement • July 6th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Development and Manufacturing Collaboration Agreement (this “Agreement”) is made effective as of February 25, 2020 (the “Effective Date”) by and between Vir Biotechnology, Inc., a Delaware corporation having an address at 499 Illinois Street, San Francisco, CA 94158 USA (“Vir”), and WuXi Biologics (Hong Kong) Limited., a Hong Kong corporation with a place of business at Building 1, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China 200131 (“WuXi”). Vir and WuXi are each hereafter referred to individually as a “Party” and together as the “Parties.”
DEFINITIVE COLLABORATION AGREEMENT By and Among GLAXO WELLCOME UK LIMITED; BEECHAM S.A.; And VIR BIOTECHNOLOGY, INC.Definitive Collaboration Agreement • July 6th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Definitive Collaboration Agreement (“Agreement”) is made and entered into as of June 9, 2020 (“Execution Date”) and is effective as of the Effective Date (as defined below), by and among Glaxo Wellcome UK Limited, a private company limited by shares organized under the laws of England having an office at [***]; and Beecham S.A., a private company limited by shares organized under the laws of Belgium having its registered place of business at [***] (together, “GSK”), and Vir Biotechnology, Inc., a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”). GSK and Vir are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
